Duration of Triple Therapy After DES in Patients with Atrial Fibrillation

Outcomes were no different between 6-month and 6-week use of clopidogrel after drug-eluting stent implantation.

For patients already receiving anticoagulation therapy who undergo drug-eluting stent implantation, one randomized trial has demonstrated that oral anticoagulation (OAC) plus clopidogrel has similar ischemic benefit, with less bleeding, compared with triple therapy (OAC and dual antiplatelet therapy [DAPT]; NEJM JW Cardiol Jun 2013) and Lancet 2013; 381:1107). In this three-center randomized trial, investigators compared 6 weeks versus 6 months of clopidogrel in 614 patients receiving OAC and aspirin after drug-eluting stent implantation.

The primary endpoint of death, myocardial infarction, definite stent thrombosis, stroke, and major bleeding at 9 months was similar in the two groups (9.8% in the 6-week group vs. 8.8% in the 6-month group;…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)